Operating
Income Loss From Equity Method Investments Net Of Dividends Or Distributions
ResMed Income Loss From Equity Method Investments Net Of Dividends Or Distributions remained flat by 0.0% to $911K in Q2 2025 compared to the prior quarter. Year-over-year, this metric grew by 297.2%, from -$462K to $911K. Over 3 years (FY 2022 to FY 2025), Income Loss From Equity Method Investments Net Of Dividends Or Distributions shows an upward trend with a -24.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2022
Last reportedQ4 2025Aug 8, 2025
Metric ID:
operating_income_loss_from_equity_method_investments_net_3458a6Historical Data
4 years
| FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|
| Value | -$8.49M | -$10.14M | -$1.85M | $3.64M |
| YoY Change | — | -19.5% | +81.8% | +297.2% |
Range-$10.14M – $3.64M
CAGR-24.6%
Avg YoY Growth+119.8%
Median YoY Growth+81.8%
Current Streak2 years growth
Income Loss From Equity Method Investments Net Of Dividends Or Distributions at Other Companies
Frequently Asked Questions
- What is ResMed's income loss from equity method investments net of dividends or distributions?
- ResMed (RMD) reported income loss from equity method investments net of dividends or distributions of $911K in Q2 2025.
- How has ResMed's income loss from equity method investments net of dividends or distributions changed year-over-year?
- ResMed's income loss from equity method investments net of dividends or distributions increased by 297.2% year-over-year, from -$462K to $911K.
- What is the long-term trend for ResMed's income loss from equity method investments net of dividends or distributions?
- Over 3 years (2022 to 2025), ResMed's income loss from equity method investments net of dividends or distributions has grown at a -24.6% compound annual growth rate (CAGR), from -$8.49M to $3.64M.